Edition:
United Kingdom

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

7.56USD
4:02pm GMT
Change (% chg)

$-0.10 (-1.31%)
Prev Close
$7.66
Open
$7.67
Day's High
$7.76
Day's Low
$7.50
Volume
11,011
Avg. Vol
88,500
52-wk High
$35.33
52-wk Low
$5.62

Latest Key Developments (Source: Significant Developments)

Dova Pharmaceuticals Appoints David Zaccardelli As Chief Executive Officer
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGES.DAVID ZACCARDELLI APPOINTED PRESIDENT AND CHIEF EXECUTIVE OFFICER.SAYS DR DAVID ZACCARDELLI APPOINTED CEO AND PRESIDENT.PROVIDES PRELIMINARY ESTIMATES OF Q4 NET PRODUCT SALES OF $2.4 TO $2.7 MILLION FOR DOPTELET.ALEX SAPIR IS NO LONGER CHIEF EXECUTIVE OFFICER EFFECTIVE AS OF DECEMBER 16.  Full Article

Dova Pharmaceuticals Inc - QTRLY Net Loss Per Share, Basic And Diluted $0.69
Thursday, 8 Nov 2018 

Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS REPORTS THIRD QUARTER 2018 OPERATING AND FINANCIAL RESULTS.DOVA PHARMACEUTICALS INC - AS OF SEPTEMBER 30, 2018, DOVA HAD $122.0 MILLION IN CASH AND EQUIVALENTS.DOVA PHARMACEUTICALS INC - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.69.DOVA PHARMACEUTICALS INC - QTRLY NET PRODUCT SALES OF $2.9 MILLION.  Full Article

Dova, Salix Enter Exclusive Co-Promotion Agreement For Doptelet
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS & SALIX ENTER INTO EXCLUSIVE CO-PROMOTION AGREEMENT FOR DOPTELET® (AVATROMBOPAG).DOVA PHARMACEUTICALS - SALIX SALES FORCE WILL BEGIN SELLING DOPTELET IN MID-OCTOBER 2018.DOVA PHARMACEUTICALS - PURSUANT TO DEAL, CO WILL PAY SALIX A QTRLY FEE BASED ON NET SALES OF DOPTELET PRESCRIBED BY GASTROENTEROLOGISTS IN THE U.S..DOVA PHARMACEUTICALS - ENTERED INTO EXCLUSIVE AGREEMENT WITH SALIX PHARMACEUTICALS TO CO-PROMOTE DOVA'S DOPTELET IN UNITED STATES.  Full Article

Dova Pharmaceuticals Inc Files For Mixed Shelf Of Upto $300 Million
Friday, 27 Jul 2018 

July 27 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $300 MILLION - SEC FILING.  Full Article

Dova Pharmaceuticals Says entered At-The-Market Equity Offering Sales Deal
Friday, 27 Jul 2018 

July 27 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS - ENTERED AT-THE-MARKET EQUITY OFFERING SALES DEAL WHERE CO MAY OFFER & SELL SHARES UP TO $100 MILLION VIA AGENT - SEC FILING.  Full Article

Dova Pharmaceuticals Reports Qtrly Loss Per Share $0.52
Wednesday, 9 May 2018 

May 9 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.52.Q1 EARNINGS PER SHARE VIEW $-0.47 -- THOMSON REUTERS I/B/E/S.  Full Article

Dova Pharmaceuticals Says On April 17, Co, Unit And SVB Entered Loan And Security Agreement
Friday, 20 Apr 2018 

April 20 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS-ON APRIL 17, CO, UNIT AND SVB ENTERED LOAN AND SECURITY AGREEMENT,PURSUANT TO WHICH SVB AGREED TO LEND CO, UNIT OF $20.0 MILLION.DOVA PHARMA SAYS LOAN MATURES ON APRIL 17, 2021 UNLESS CO ACHIEVES SPECIFIED REVENUE MILESTONE, THEN MATURITY DATE TO BE EXTENDED BY A YEAR - SEC FILING.  Full Article

Dova Pharmaceuticals Inc - Supplemental NDA For Avatrombopag in ITP To Be Submitted In Second Half Of 2018
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS PROVIDES UPDATE ON DEVELOPMENT STRATEGY FOR AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT).DOVA PHARMACEUTICALS INC - SUPPLEMENTAL NDA FOR ITP TO BE SUBMITTED IN SECOND HALF OF 2018.DOVA PHARMACEUTICALS INC - PHASE 3 CLINICAL TRIAL FOR CIT TO BEGIN IN Q2 OF 2018.  Full Article

Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE AVATROMBOPAG NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW.DOVA PHARMACEUTICALS INC - PDUFA GOAL DATE FOR AN FDA DECISION IS MAY 21, 2018 FOR NDA​.  Full Article

Dova Pharmaceuticals reports third quarter results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Dova Pharmaceuticals Inc :Dova Pharmaceuticals reports third quarter 2017 operating and financial results.Dova Pharmaceuticals Inc - qtrly ‍net loss per share, basic and diluted $0.38​.  Full Article